Biocon Biologics & Serum Institute Life Sciences Announce Stra | Rajesh Palviya™
Biocon Biologics & Serum Institute Life Sciences Announce Strategic Alliance BBL will have access to 100 million doses of vaccines annually & commercialization rights of SILS vaccine portfolio for global markets SILS to receive 15% stake in BBL at a post-money vals of $4.9bn